MEP spinal anesthesia allows for earlier ambulation for patients undergoing total hip arthroplasty.
Pectoral nerve blocks were found to diminish pain and opioid use following pacemaker or implantable cardioverter defibrillator placement in children.
Recommendations are presented regarding anesthesia procedures for emergency operations in patients with suspected or confirmed COVID-19.
Managing moderate or severe postoperative pain, which affects 75% of patients in the United States, remains a challenge for physicians.
The FDA has accepted the resubmitted NDA for XaraColl® for the management of postsurgical pain after open inguinal hernia surgery.
A systemwide, multipronged pain management and opioid reduction program can significantly reduce opioid discharge prescriptions written for more than five days.
The FDA has approved Anjeso (meloxicam injection; Baudax Bio) for the management of moderate to severe pain, alone or in combination with NSAIDs in adult patients.
Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.
Production and distribution of Excedrin Extra Strength and Excedrin Migraine products have been temporarily stopped.
A ready-to-use formulation of Caldolor (ibuprofen injection) has been made available by Cumberland Pharmaceuticals.